School of Medicine
Showing 401-450 of 517 Results
-
Aditi Sharma
Basic Life Res Scientist, Pediatrics - General Pediatrics
Current Role at StanfordResearch Scientist
-
Victoria "Vicki" Spencer
Adm Assoc 4, Pediatrics - Peds/Critical Care
BioA graduate of Purdue University, Vicki brings over 20 years of executive administrative support experience to her position at Stanford Medicine.
Prior to taking this role, Vicki supported the Chief Medical Officer and Chief Dental Officer for a group of Federally Qualified Health Centers (FQHC). She has also provided executive support to individuals in the field(s) of healthcare, food equity, and pre-clinical drug development.
Her passions are health equity and whole-system integrated care. -
Han Sun
Postdoctoral Scholar, Genetics
Biostatistician 2, Pediatrics - EndocrinologyBioHan had been a postdoc with Dr. Steinmetz at the genetics department for five years, working on both cancers and heart diseases, trying to understand the mechanisms linking from variants to disease phenotypes. This led to a few very interesting findings of aberrant splicing regulation, such as splicing-mediated readthrough stabilization (SRS), one more mechanism for oncogene activation in multiple types of cancers, and tissue-specific splicing of a mitochondrial inner membrane protein, suggesting a molecular connection between deficiency in energy-supplying and dilated cardiomyopathy.
After being a senior computational biologist with Dr. Gloyn, who has been dedicated to the research of type 2 diabetes for decades, Han switched to the field of this multifactorial metabolic disease. It did take some courage to make such a switch at his post-postdoc stage, however, Han has a consistent interest in studying PG&E, which is not pacific gas and electric nearby, but the interaction between phenotype, genotype, and environment. With years of hands-on experience in statistical modeling and the analysis of next-generation sequencing and mass spectrometry data, in addition to a good understanding of disease genetics, cancer biology, and systems biology, Han is highly confident that he will enjoy the adventure and contribute to our understanding of diabetes. -
Jacqueline Sunderland
Adm Assoc 3, Pediatrics - Endocrinology
Current Role at StanfordAdministrative Associate, Pediatric Endocrinology & Diabetes
-
Swaraj Thaman
Life Science Research Professional, Pediatrics - Endocrinology
Current Role at StanfordLife Science Research Professional 1, Translational Genomics of Diabetes Laboratory, Department of Pediatrics - Endocrinology, School of Medicine
-
George F Tidmarsh
Adjunct Professor, Pediatrics - Neonatology
BioDr. Tidmarsh received M.D. and Ph.D. from Stanford University, where he also completed fellowship training in Pediatric Oncology and Neonatology and is currently Adjunct Faculty of Pediatrics and Neonatology. He served as clinical faculty at Stanford for a number of years after fellowship prior to devoting his full time to clinical research and development in order to bring new treatments through the FDA approval process. Dr. Tidmarsh was President, Chief Executive Officer, Secretary and a Director of La Jolla Pharmaceutical Company from January 2012 until November 2019. While at La Jolla, Dr. Tidmarsh helped discover the use of angiotensin II for the treatment of shock and led all aspects of the development including approval by the US FDA and the EMA for the treatment of patients suffering from distributive shock. He also led the development of artesunate for the treatment of severe malaria, now pending action for potential approval at the FDA. Dr. Tidmarsh has over 30 years of experience in biotechnology, including the successful clinical development of three FDA-approved drugs. He previously served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. He also founded Threshold Pharmaceuticals, Inc. and held senior positions at Coulter Pharmaceutical, Inc. (acquired by GlaxoSmithKline) and SEQUUS Pharmaceuticals, Inc. (acquired by Johnson & Johnson). While at Coulter and SEQUUS, Dr. Tidmarsh led the clinical development of BEXXAR and Doxil, respectively, two FDA-approved anti-cancer agents.
At Stanford, Dr. Tidmarsh is devoted to teaching clinical research and development to residents, fellows and junior faculty. In addition, he is working to help improve the quality of medical care through various efforts which include serving on the board of Lucile Packard Foundation for Children's Health.
